SpartaLabs
0
SpartaLabs Research · June 17, 2026

GHK-Cu: A Research Overview

A research-library overview of GHK-Cu — chemistry, copper-binding properties, pharmacological classification, regulatory status, and discovery history. Educational reference.

ghk-cucopper-peptidetripeptidetissue-remodeling

Introduction

GHK-Cu (glycyl-L-histidyl-L-lysine–copper(II) complex) is a naturally occurring tripeptide–metal complex found in human plasma, saliva, and urine. First isolated from human albumin in 1973 by Loren Pickart and Monroe Thaler at the University of California, San Francisco, during research on hepatocyte growth regulation [1], the compound has since accumulated a peer-reviewed literature spanning copper biochemistry, extracellular matrix biology, and wound-healing research spanning more than five decades. This article provides an educational reference overview of GHK-Cu's chemical identity, pharmacological classification, and regulatory status. The molecular mechanisms underlying these reported activities are examined separately in the GHK-Cu mechanism of action article.

Background

Copper is an essential trace element required as a catalytic cofactor for a range of cuproenzymes, including cytochrome c oxidase, superoxide dismutase (Cu,Zn-SOD), and lysyl oxidase. The transport and cellular delivery of copper in biological systems involves several carrier molecules, among them albumin, ceruloplasmin, and small copper-binding peptides present in plasma.

Pickart and Thaler's 1973 report identified a tripeptide activity in serum albumin fractions that prolonged the survival of normal hepatocytes and stimulated proliferation in hepatoma cell lines in co-culture experiments [1]. That activity was subsequently characterized chemically and reported by Schlesinger, Pickart, and Thaler in 1977 to correspond to the sequence glycyl-L-histidyl-L-lysine [2].

The copper(II)-binding capacity of this tripeptide was recognized as central to its observed biological activity. The tripeptide displays a copper-binding affinity in the nanomolar range — comparable to the copper transport site on albumin — and forms a stable 1:1 complex with Cu²⁺ [3]. Naturally occurring GHK has been detected in human plasma at concentrations reported to be in the high-nanomolar to low-micromolar range, with observed variation across biological contexts [8].

Chemistry and Structure

GHK is a tripeptide composed of three proteinogenic amino acids: glycine, L-histidine, and L-lysine, in that N-to-C terminal order. Its molecular formula is C₁₄H₂₄N₆O₄, with a molecular weight of approximately 340.4 daltons for the free tripeptide. The copper(II) complex (GHK-Cu) is formed by coordination of Cu²⁺ primarily through the alpha-amino nitrogen of glycine, the amide nitrogen of the peptide bond, and the imidazole nitrogen of histidine, with additional contribution from the lysine residue — a binding mode characterized as square-planar or distorted-square-planar geometry under physiological conditions [3].

The tripeptide sequence Gly-His-Lys is notable for appearing within the alpha-2(I) chain of type I collagen. Research has suggested that GHK may be liberated at wound sites by protease activity on collagen, where it could act locally as a signaling molecule [4]. This structural relationship to collagen has informed several lines of investigation into GHK-Cu's role in connective tissue biology.

Pharmacological Classification

GHK-Cu is classified in the research literature as a copper-chelating tripeptide, or more broadly as a copper-binding peptide (CBP), within the category of metallopeptides. It is distinct from copper-transporting chaperone proteins (such as ATOX1 or CCS) in that it is a small-molecule peptide rather than a folded protein.

In terms of its reported pharmacological profile, GHK-Cu has been investigated as a modulator of extracellular matrix remodeling, characterized by effects on both matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) [5]. Research has also described antioxidant properties related to the copper-binding geometry of the complex [6].

GHK-Cu does not map to a single receptor subtype in the fashion of G-protein-coupled receptor ligands or kinase inhibitors. Its reported biological actions appear to involve multiple cellular pathways. Research published in 2018 using the Broad Institute Connectivity Map documented associations between GHK and expression changes across a large set of human genes, including genes related to DNA repair, anti-inflammatory signaling, and extracellular matrix homeostasis [7] — an observation that has been described as consistent with GHK acting through a broad transcriptional program rather than a single defined receptor axis. A related copper-independent regenerative peptide studied in wound-healing contexts is BPC-157, which has been characterized through distinct signaling pathways in the peer-reviewed literature.

Regulatory Status

GHK-Cu is not approved by the United States Food and Drug Administration (FDA) for any therapeutic indication in humans. In the United States, GHK-Cu is sold as a research-use-only material. In certain topical formulations it has additionally been used as a cosmetic ingredient under the FDA's definition of cosmetics (21 U.S.C. § 321(i)); cosmetic use is a separate regulatory classification and does not constitute or imply any drug approval or determination of therapeutic efficacy.

GHK-Cu has been investigated in wound-dressing contexts in animal research models. The compound is classified as a research-use-only material at SpartaLabs and is not intended for human administration. Research-grade GHK-Cu from SpartaLabs is verified by independent third-party HPLC analysis and mass spectrometry confirmation on every batch.

Discovery History

The isolation of GHK from albumin fractions was reported in 1973 in Nature New Biology [1]. Pickart subsequently refined the characterization of the active fraction, and the full amino acid sequence was confirmed in 1977 [2]. Early research in the late 1970s and early 1980s explored the compound's copper-binding properties, culminating in the 1980 Nature hypothesis that the tripeptide may facilitate cellular copper uptake [3].

Systematic investigation of GHK-Cu's effects on connective tissue synthesis accelerated through the 1980s and 1990s, with in vitro fibroblast studies [4] and in vivo wound-chamber experiments in rodent models [9] appearing in that period. The early 2000s brought characterization of metalloproteinase modulation [5], and subsequent decades have produced an expanding body of literature on gene expression profiling and tissue-remodeling mechanisms. That research progression is discussed in detail in the companion history article in this library.

References

  1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85–87. PMID: 4349963. https://pubmed.ncbi.nlm.nih.gov/4349963/

  2. Schlesinger DH, Pickart L, Thaler MM. Growth-modulating serum tripeptide is glycyl-histidyl-lysine. Experientia. 1977;33(3):324–325. PMID: 858356. https://pubmed.ncbi.nlm.nih.gov/858356/

  3. Pickart L, Lovejoy S. Biological activity of human plasma copper-binding growth factor glycyl-L-histidyl-L-lysine. Methods Enzymol. 1987;147:314–328. PMID: 7453802. [See also: Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715–717. PMID: 7453802.] https://pubmed.ncbi.nlm.nih.gov/7453802/

  4. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343–346. PMID: 3169264. https://pubmed.ncbi.nlm.nih.gov/3169264/

  5. Simeon A, Wegrowski Y, Bontemps Y, Maquart FX. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. J Invest Dermatol. 2000;115(6):962–968. PMID: 11045606. https://pubmed.ncbi.nlm.nih.gov/11045606/

  6. Pickart L, Vasquez-Soltero JM, Margolina A. GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes. Cosmetics. 2015;2(3):236–247. DOI: 10.3390/cosmetics2030236. https://doi.org/10.3390/cosmetics2030236

  7. Pickart L, Vasquez-Soltero JM, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID: 29987210. PMC: PMC6073405. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/

  8. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969–988. PMID: 18644225. https://pubmed.ncbi.nlm.nih.gov/18644225/

  9. Pickart L, Freedman JH, Loker WJ, Peisach J, Perkins CM, Stenkamp RE, Weinstein B. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715–717. [In vivo wound-chamber studies are documented in: Proc Natl Acad Sci USA. 1994;91:11069–11073. PMC: PMC288419.] https://pmc.ncbi.nlm.nih.gov/articles/PMC288419/

Frequently asked questions

  • What is GHK-Cu?

    GHK-Cu (glycyl-L-histidyl-L-lysine–copper(II) complex) is a naturally occurring tripeptide–metal complex found in human plasma, saliva, and urine. It was first isolated from human albumin in 1973 by Loren Pickart and Monroe Thaler at the University of California, San Francisco.

  • What is the chemical structure of GHK-Cu?

    GHK is a tripeptide composed of glycine, L-histidine, and L-lysine. Its molecular formula is C₁₄H₂₄N₆O₄ with a molecular weight of approximately 340.4 daltons for the free tripeptide. The copper(II) complex is formed by coordination of Cu²⁺ through a square-planar or distorted-square-planar geometry involving the alpha-amino nitrogen of glycine, the amide nitrogen of the peptide bond, and the imidazole nitrogen of histidine.

  • Is GHK-Cu FDA approved?

    GHK-Cu is not approved by the United States Food and Drug Administration for any therapeutic indication in humans. In the United States it is sold as a research-use-only material. In certain topical formulations it has additionally been used as a cosmetic ingredient, a separate regulatory classification that does not constitute or imply any drug approval.

  • How was GHK-Cu discovered?

    The isolation of GHK from albumin fractions was reported in 1973 in Nature New Biology by Pickart and Thaler during research on hepatocyte growth regulation. The full amino acid sequence was confirmed in 1977, and the copper(II)-binding capacity of the tripeptide was recognized in 1980 as central to its observed biological activity.

  • What pharmacological class does GHK-Cu belong to?

    GHK-Cu is classified in the research literature as a copper-chelating tripeptide, or more broadly as a copper-binding peptide (CBP), within the category of metallopeptides. It is distinct from copper-transporting chaperone proteins in that it is a small-molecule peptide rather than a folded protein.

GHK-Cu Research Overview | SpartaLabs Research Library — SpartaLabs